Scholarlink

Background <p>Polygenic risk scores (PRS) estimate an individual’s germline genetic predisposition to a quantitative trait and/or risk of disease. Several PRS have been developed for cancer risk with the goal of improved risk screening. Here, we sought to establish whether PRS for cancer risk and other common traits may influence survival for patients with cancer.</p> Methods <p>We conducted a PRS survival analysis using 23,770 cancer patients of European ancestry from the Dana-Farber Cancer Institute Profile cohort.</p> Results <p>We identified an association between PRS for breast cancer risk and longer patient survival (HR = 0.89 (95% CI: 0.84–0.95), <i>p</i> = 1.50 × 10<sup>–4</sup>, &lt; 5% FDR), implying that individuals at high genetic risk had better outcomes. High PRS individuals were also significantly less likely to harbor somatic TP53 mutations, consistent with having less aggressive tumors. This association persisted when including tumor grade and became more protective when restricting to ER-negative tumors (HR = 0.78 (95% CI: 0.68–0.89), <i>p</i> = 1.69 × 10<sup>–4</sup>). Potential confounders such as hormone receptor status, age, grade, stage, and ER-targeted therapy did not fully explain this association, nor was there statistical evidence of index event bias at individual variants. We did not observe significant associations between cancer risk and survival for other cancers, suggesting that this mechanism may be largely unique to breast cancer. However, we did observe associations between shorter survival and type 2 diabetes, bipolar, and pancreatitis PRS (1% FDR).</p> Conclusions <p>These findings suggest that higher germline risk may predispose individuals to less aggressive breast cancer tumors and provide novel insights into breast cancer development and prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between polygenic risk and survival in breast cancer patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月28日

查看全文
  • Danielle E. Kurant,
  • Stefan Groha,
  • Yi Ding,
  • Chris German,
  • Wei Wang,
  • Julie M. Granka,
  • Michael V. Holmes,
  • Stella Aslibekyan,
  • Adam Auton,
  • Elizabeth Babalola,
  • Robert K. Bell,
  • Jessica Bielenberg,
  • Ninad S. Chaudhary,
  • Zayn Cochinwala,
  • Sayantan Das,
  • Emily DelloRusso,
  • Payam Dibaeinia,
  • Sarah L. Elson,
  • Nicholas Eriksson,
  • Chris Eijsbouts,
  • Teresa Filshtein,
  • Pierre Fontanillas,
  • Davide Foletti,
  • Will Freyman,
  • Zach Fuller,
  • Éadaoin Harney,
  • Alejandro Hernandez,
  • Barry Hicks,
  • David A. Hinds,
  • M. Reza Jabalameli,
  • Ethan M. Jewett,
  • Yunxuan Jiang,
  • Sotiris Karagounis,
  • Lucy Kaufmann,
  • Matt Kmiecik,
  • Katelyn Kukar,
  • Alan Kwong,
  • Keng-Han Lin,
  • Yanyu Liang,
  • Bianca A. Llamas,
  • Aly Khan,
  • Steven J. Micheletti,
  • Matthew H. McIntyre,
  • Meghan E. Moreno,
  • Priyanka Nandakumar,
  • Dominique T. Nguyen,
  • Jared O’Connell,
  • Steve Pitts,
  • G. David Poznik,
  • Alexandra Reynoso,
  • Shubham Saini,
  • Morgan Schumacher,
  • Leah Selcer,
  • Anjali J. Shastri,
  • Jingchunzi Shi,
  • Keaton Stagaman,
  • Teague Sterling,
  • Qiaojuan Jane Su,
  • Joyce Y. Tung,
  • Susana A. Tat,
  • Vinh Tran,
  • Xin Wang,
  • Catherine H. Weldon,
  • Amy L. Williams,
  • Peter Wilton,
  • Suyash S. Shringarpure,
  • Alexander Sasha Gusev

摘要

Background

Polygenic risk scores (PRS) estimate an individual’s germline genetic predisposition to a quantitative trait and/or risk of disease. Several PRS have been developed for cancer risk with the goal of improved risk screening. Here, we sought to establish whether PRS for cancer risk and other common traits may influence survival for patients with cancer.

Methods

We conducted a PRS survival analysis using 23,770 cancer patients of European ancestry from the Dana-Farber Cancer Institute Profile cohort.

Results

We identified an association between PRS for breast cancer risk and longer patient survival (HR = 0.89 (95% CI: 0.84–0.95), p = 1.50 × 10–4, < 5% FDR), implying that individuals at high genetic risk had better outcomes. High PRS individuals were also significantly less likely to harbor somatic TP53 mutations, consistent with having less aggressive tumors. This association persisted when including tumor grade and became more protective when restricting to ER-negative tumors (HR = 0.78 (95% CI: 0.68–0.89), p = 1.69 × 10–4). Potential confounders such as hormone receptor status, age, grade, stage, and ER-targeted therapy did not fully explain this association, nor was there statistical evidence of index event bias at individual variants. We did not observe significant associations between cancer risk and survival for other cancers, suggesting that this mechanism may be largely unique to breast cancer. However, we did observe associations between shorter survival and type 2 diabetes, bipolar, and pancreatitis PRS (1% FDR).

Conclusions

These findings suggest that higher germline risk may predispose individuals to less aggressive breast cancer tumors and provide novel insights into breast cancer development and prognosis.